Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs 10X Genomics Inc (TXG) Price & Performance

iShares MSCI Germany (DAX)Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs 10X Genomics Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.42B), while 10X Genomics Inc trades at $79.19 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 7.1× iShares MSCI Germany (DAX)'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and 10X Genomics Inc for 92 Days on average.

EWGTXG
Market Cap
$1.42B$10.07B
Volume
1,110,5735,657,286
Sector
Broad Market / FactorHealth
52-Week High
$44.59$97.74
52-Week Low
$38.08$11.48
Typical Hold Time
56 Days92 Days
Enterprise Value
—$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.

Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWG

No sentiment data available yet.

TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →